Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

Lignende værker

• Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease
  af: Zimran, Ari, et al.
  Udgivet: (2016)
• Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
  af: Zimran, Ari, et al.
  Udgivet: (2018)
• Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118(22):5767–5773.
  af: Zimran, Ari, et al.
  Udgivet: (2012)
• Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa
  af: Zimran, Ari, et al.
  Udgivet: (2018)
• Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease
  af: Gupta, Punita, et al.
  Udgivet: (2017)